urgical and interventional revascularization in patients with critical limb ischemia (CLI) could prevent limb amputation, improve quality of life, and prolong survival. The limb salvage rate with direct revascularization is 82% over a four-year period, while indirect revascularization has a salvage rate of 64% (1, 2). However, as the affected arteries are mostly segmented, diffused, and located peripherally, the efficacy of surgical revascularization remains limited (3). Therefore, additional therapy, such as angiogenesis, is absolutely essential to improve the success of limb salvage.
ii • Diagnostic and Interventional Radiology stent insertion procedure), analyzed (Table) , and transplanted on the same day within two hours of isolation.
PB-MNCs were isolated by apheresis using a COBE ® Spectra Apheresis System (Gambro, Lakewood, Colorado, USA) with a 12 F 16 cm You-Bend hemodialysis catheter (Arrow International, Reading, Pennsylvania, USA) inserted into the patient's subclavian vein. Apheresis was performed at an 80 mL/ min blood flow rate for approximately three hours by processing 15 L of blood. Immediately after isolation, 7.9×10 9 autologous PB-MNCs in a 50 mL volume was infused into the left femoral artery (Fig. 2c) .
The ABPI was measured using an ABPI device (VP-2000, Colin Medical Technology, Komaki, Japan) before and after the interventional procedures. Following PB-MNC transplantation, ABPI and Rutherford categories were monitored 3, 7, 14, 30, 60, and 180 days as well as one and four years postprocedure. Doppler ultrasonographic examination of dorsalis pedis artery in left leg was performed using an Acuson Sequoia 512 ultrasound unit (GE Healthcare, Mountain View, California, USA) and a linear array transducer with a 5 MHz frequency and 8L5 probe. Peak systolic velocity (PSV) and end diastolic velocity (EDV) of blood flow (cm/s) in the dorsalis pedis artery were measured four days prior to and after interventional procedures. Post-stem cell therapy outcome was evaluated by monitoring blood flow 3, 15, and 25 days as well as four years after the procedure.
The combinatorial approach, first with angioplasty and stent insertion followed by PB-MNC transplantation into the left leg alone, was safe and effective in terms of an improvement in Rutherford's clinical categories of chronic limb ischemia from grade III category 5 to 0-0. Furthermore, this approach saved the patient from major amputations without any complications during the long-term follow-up for four years.
Production of WBC in peripheral blood was enhanced four-fold and MNC 1.5-fold by stimulation of bone marrow with G-CSF for four days (Table) . G-CSF also stimulated CD133 + and CD34 + cells by 18-fold. Levels of CD133 + cells peaked on the third day and CD34 + cells on the fourth day upon G-CSF stimulation. Other cells, such as red blood cells, hemoglobin, platelets, neutrophils, and nucleated red blood cells, were not dramatically stimulated by G-CSF, except for neutrophils, which increased five-fold (Table) .
(PA), tibioperoneal arteries, and dorsalis pedis were barely visualized (Fig. 2a) .
Prestent balloon angioplasty was performed using a 3 mm/10 cm size balloon (Savvy Balloon Catheter, Cordis, Warren, New Jersey, USA) at the left SFA (Fig. 2b) . Two stents of 6 mm/10 cm and 7 mm/10 cm (S.M.A.R.T. ® Control ® Nitinol Stent, Cordis) were implanted at the left SFA. Post-stent balloon angioplasty was performed using a 5 mm/10 cm size balloon (PowerFlex Extreme, Cordis). The left SFA was successfully dilated; however, the PA and tibioperoneal arteries were not treated ( Fig. 2c  and 2d ). The procedure improved the left leg Rutherford grade III-category 5 to II-4 within three days.
G-CSF (Leucostim ® , Dong-A Pharmaceuticals, Seoul, Korea) was injected (5 µg/kg) into the patient at 6:00 pm for four days before transplantation, and the blood was analyzed at 6:00 am on the day following transplantation. Stimulation of MNC production and white blood cell (WBC) count by G-CSF was monitored. CD34 + /CD133 + cells were counted by flow cytometry on a Cytomics FC500 flow cytometer (Beckman Coulter Inc., Fullerton, California, USA). PB-MNCs were isolated by leukapheresis four days after G-CSF stimulation (four days after the 
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MNCs collected by leukapheresis were comprised of 63% lymphocytes, 38% monocytes, 0.17% CD133 + , and 0.48% CD34 + cells (Table) . A total of 7.9×10 9 PB-MNCs in 50 mL normal saline was transplanted by intra-arterial injection into the left SFA ( Fig. 2c and 2d) . A remarkable change in visible symptoms was observed, with decreased redness and swelling in the left foot within three days of stem cell transplantation (Fig. 1) . In addition, Rutherford classification improved from grade II-4 to grade 0-1 by the time of transplantation, reaching 0-0 in two months and remaining consistent for the four years of the study. At the time of minor amputation of third, fourth, and fifth toes of the left leg (seven months after transplantation), bleeding was observed (Figs. 1  and 3 ).
Prior to start of the treatment, ABPI was not in the detectable range. Postperipheral blood stem cells (PBSC) transplantation, it showed a dramatic increase to 0.63 after three days, peaking at 0.68 after two months, and maintaining consistent levels for four years. Doppler ultrasonographic examination of the dorsalis pedis artery in the left leg after interventional treatment by ballooning and stent insertion showed an increase in PSV from 14.8 to 28.5 cm/s and EDV from 11.7 to 19.9 cm/s, respectively. The PBSC transplantation within three days further improved the PSV to 34.4 cm/s and EDV to 22.9 cm/s. After 15 days, PSV and EDV were 28.5 and 19.9 cm/s, respectively, with measurements of 35.3 and 20.8 cm/s after 25 days, and 36.1 and 21 cm/s after four years, respectively.
Discussion
In this report, we presented a combinatorial approach in a CLI patient that is both safe and effective without any side effects, suggesting its potential usefulness as a better option compared to previous single treatment strategies. The major outcomes from this long-term follow-up after treatment were saving the patient from the threat of major amputation, and decreased resting pain, angiogenesis and revascularization.
Several therapeutic studies have reported effective use of autologous stem cells for PAD with a rapid amelioration of symptoms (8) , as was observed in the present study. Many investigators, however, still prefer BM-MNCs for treatment (4, 5) . We used PBSCs to treat CLI PAD disease, as isolation of PBSCs is easier, convenient, less painful, more practical, and also safe and effective (6, 9) . G-CSF increased the number of WBC and CD34 positive cells in the peripheral blood, and thus large volume leukapheresis is commonly used for harvesting the PB-MNC fraction (10) . Other medications, such as iloprost (prostacyclin, PGI2), cilostazol (phosphodiesterase-3 inhibitor) and others are widely used in CLI patients to relieve symptoms and signs of ischemia. Because iloprost increases the endothelial progenitor cell number in peripheral blood in vivo, it may have a direct effect on therapeutic angiogenesis (11, 12) .
As the peripheral arteries are damaged in CLI PAD patients, we aimed to infuse the stem cells by the intra-arterial route in order to directly supply the cells to the affected area, as was performed in other trials in patients with infrapopliteal peripheral artery occlusive disease (9) . Intra-arterial administration has many advantages over intramuscular administration, including the use of the native delivery route, the automatic penetration of damaged tissue by the cells, and the arrival of cells to the target tissue through chemotaxis, at least after the second circulation (13, 14) .
Bleeding observed at the time of the minor amputation, which occurred months after cell transplantation, confirmed the new and established angiogenesis and vascularization (Suppl. Fig.) . The results mainly showed rapid relief of pain wit hout the need for major amputations. Although our results using stem cell therapy in CLI PAD patients are quite promising, it is critical to keep in mind possible unwanted angiogenesis and death due to MNC therapy. Further long-term, randomized controlled clinical trials are required to substantiate the efficacy of this comprehensive approach to treat CLI PAD.
In summary, here we present a case report of a combinatorial approach of interventional revascularization and consecutive stem cell delivery through the intra-arterial administration of G-CSF mobilized PB-MNC in a CLI patient as an effective treatment without any side effects.
